Valproate received its license for the treatment of epilepsy in the UK in 1972. It then went on to become one of the most commonly used anti-seizure medications (ASMs) for decades. Over time, case series’ and retrospective studies raised concerns of teratogenicity, [1] but these did not appear to substantially permeate the public or medical community consciousness until much later with the publication of results from the large prospective international registries in the mid-2000s (for detailed reference list see [2]).
31
JUL
JUL
0